Business Wire

SETi: U.S. Court Affirms Principle of Protecting Domestic Patent Technologies, Permanently Bans Infringing Products

24.2.2026 15:00:00 CET | Business Wire | Press Release

Share

In February 2026, a U.S. federal court ruled that Laser Components, a century-old global optics company, had infringed patents held by Sensor Electronic Technology, Inc. (SETi), a U.S.-based company that has focused on opto-semiconductor R&D and manufacturing for the past 25 years. The court ordered a permanent injunction banning the sale of the infringing products. The ruling applies not only to the manufacture and sale of products using the infringing technology, but also to employees and executives who cooperated in or were involved in the infringement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223103204/en/

Opto-Semiconductor Structure & Applied Patented Technologies (image: SETi)

The patented technology is regarded as one of the core technologies for the future opto-semiconductor market, which is projected to grow to approximately $50 billion within the next decade—about one quarter the size of the memory semiconductor market. By converting electrical energy into light energy, the technology is expected to be used in AR glasses that could replace smartphones, as well as in high-bandwidth memory (HBM) semiconductors to reduce AI-related power consumption. The essence of the patent lies in optimizing semiconductor current and multi-layer structures to maximize photon generation while minimizing photon loss within the semiconductor—thereby significantly enhancing performance.

A key aspect of this ruling is that the scope of infringement was not limited to specific products. The court prohibited the manufacture, sale, and importation of all products produced using processes similar to the patented technology. The written judgment further clarified that the injunction applies not only to the company’s executives and employees, but also to any third parties who assisted or participated in the infringing activities.

The decision follows the same legal context as a similar patent infringement case involving SETi in 2019. In that case, a former SETi technical employee relocated to China, established and operated an opto-semiconductor company, and later returned to the United States to found Bolb Inc., which was found to have infringed SETi’s patents. The court issued injunctions against Bolb employees and related parties. In the present Laser case, the infringing products were manufactured by a company established by a former executive of Seoul Viosys—SETi’s long-time OEM manufacturing partner—and were subsequently imported and sold by Laser Components. The court delivered a firm judgment against the misappropriation of the underlying technology.

Rakesh Jain, CEO of SETi, stated, “Birth is not fair, but opportunity must be fair.” He added, “Without opto-semiconductors, the United States could not manufacture automobiles or aircraft, and our homes and streets would fall into darkness. Yet today, everyone talks only about silicon semiconductors and AI, while the national security risks associated with opto-semiconductors are rarely mentioned.”

He further noted, “Some large corporations are using low-cost products that infringe patents. To manufacture products essential to the United States, SETi has secured a 25,000-square-meter site and, together with Seoul Viosys in Korea, has invested billions of dollars over the past 25 years. However, we are currently operating at less than 10% capacity.” He urged, “For the sake of national security, opto-semiconductor patent technologies must be protected, and the government should pay special attention to preventing U.S. patents from being sold to foreign companies.”

About Sensor Electronic Technology, Inc. (SETi)

SETi is a U.S.-based innovation company that developed and commercialized the world’s first Deep UV LED opto-semiconductor technology. Headquartered in Columbia, South Carolina, SETi, the subsidiary of Seoul Semiconductor (KOSDAQ: 046890), has built a strong portfolio of more than 600 foundational patents and continues to develop and manufacture its own EPI technology in-house. SETi generates approximately $10 million in annual revenue across global applications, including medical, industrial, and environmental sectors, and continues to lead technological advancement in the field. For more information, visit: http://www.s-et.com/en/.

About Seoul Viosys

Seoul Viosys possesses the technological capability to produce full-spectrum opto-semiconductor chips from 200nm to 1,400nm, supported by over 6,000 patents. The company manufactures VCSEL (Vertical Cavity Surface Emitting Laser) and laser diodes, and mass-produces the world’s first “WICOP Pixel,” which integrates R, G, and B for displays into a single chip. Founded in 2002, Seoul Viosys currently holds the world’s No. 1 market share in UV LED and, together with its parent company Seoul Semiconductor—which holds 15,000 patents—continues to strengthen its technological leadership in the global market. For more information, visit: www.seoulviosys.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223103204/en/

Contacts

Seoul Semiconductor Co., Ltd.
Jin (Jinseop Jung)
jjs8732@seoulsemicon.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye